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Aim: Aim of this research was to develop and validate a simple, efficient and reproducible high-
performance liquid chromatography method to measure phenytoin concentrations in human plasma 
Study Design: Linearity, selectivity, sensitivity, accuracy and precision of the analytical methods 
were validated according to ICH guidelines. 
Methodology: The method employed a Phenomenex C18 column kept at 25ºC. The mobile phase 
consisted of a 0.05 M potassium dihydrogen phosphate buffer solution (pH 2.8) and methanol in a 
ratio of 60:40, respectively. The flow rate of the mobile phase was 0.7 mL/min. Phenytoin was 
detected at a wavelength of 250 nm. 
Results: Phenytoin was eluted at 7.4 minutes with no interference with the other components of the 
human plasma. The method was linear in the range of 1-25 μg/mL (R2 = 0.9998). The LOD and 
LOQ were calculated as 0.07 μg/mL and 0.20μg/mL, respectively. Recovery, tested in the range of 
5-20 μg/mL, was found to be 99.21 - 102.09%. Intraday and interday precision RSDs were 0.65 and 











0.29%, respectively.  
Conclusion: The proposed method is fast, reliable and reproducible, and can be recommended to 
measure free phenytoin levels in the blood. 
 
 




Phenytoin (PHT) is an anticonvulsant medication 
marketed in the U.S. as Dilantin™. This drug has 
been indicated for the management of 
generalized tonic-clonic seizures, complex partial 
seizures, and for the prevention of seizures after 
head trauma and neurosurgery [1,2]. There is 
interest in examining the activity of the drug due 
to its narrow therapeutic index, nonlinear 
pharmacokinetics and the ability of various 
compounds to modify the concentrations of 
phenytoin in the blood [2-5]. Drugs in the body 
exist in two forms bound and unbound. Only 
unbound (free) drug reaches the active site, 
interacts with receptors and produces a 
therapeutic effect. Free drug is a predictor of 
clinical efficacy or toxicity [6-8]. PHT is 
approximately 90% bound to plasma proteins [9-
11]. Changes in unbound concentrations of PHT 
can lead to exaggerated pharmacologic 
response and toxicity. The development of side 
effects also correlates better with free phenytoin 
concentrations than with total concentrations [12-
14]. PHT, as a drug with nonlinear 
pharmacokinetics and narrow therapeutic index, 
may produce major changes in the 
pharmacological effect with the only small 
variations in its unbound plasma concentrations. 
Monitoring of free PHT plasma levels is                
required to avoid unexpected alterations                        
in pharmacologic response, to achieve the 
efficacy of phenytoin and to avoid phenytoin 
intoxication. Unbound phenytoin plasma 
concentrations should be measured in                
patients rather than calculated [15]. Our                
study aimed to develop a simple, efficient                
and reproducible high-performance liquid 
chromatography (HPLC) method to assess 
unbound PHT levels in human plasma.              
Previous studies have measured PHT levels 
using HPLC methods outside plasma [16,17], 
involved solid-phase extraction protocols               
[18] as well as detected PHT concentrations                 
in biological fluids [19-25]. This novel HPLC 
method was used to assess free plasma 
concentrations of phenytoin in drug-drug 
interaction studies [26]. 
 
2. MATERIALS AND METHODS 
 
2.1 Chemicals and Reagents 
 
Phenytoin sodium (5,5-Diphenylhydantoin 
sodium salt), dimethyl sulfoxide (DMSO), HPLC-
grade methanol, HPLC-grade water and 0.22 μm 
Stericup™ Sterile Vacuum Filter Units were 
obtained from Fisher Scientific (New Hampshire, 
USA). Potassium dihydrogen phosphate and 
Centrifree® Ultrafiltration Devices were 
purchased from EMD Millipore (Massachusetts, 
USA). Human plasma was obtained from Valley 
Biomedical (Virginia, USA). 
 
2.2 Instrument and Chromatographic 
Conditions 
 
An Agilent 1100 series HPLC system with 
autosampler and UV detector was used for the 
study. A Phenomenex Kinetex C18 LC column 
(250 x 4.6 mm) was operated at 25ºC. An 
isocratic method was utilized to elute the analyte 
with a mobile phase flow rate of 0.7 mL/min. The 
injection volume was 20 µL for all 
samples.Phenytoin was detected at a 
wavelength of 250 nm. 
 
2.3 Mobile Phase Preparation 
 
The mobile phase consisted of a 0.05 M 
potassium dihydrogen phosphate (KH2PO4) 
buffer solution (pH adjusted to 2.8 with 
phosphoric acid) and methanol (MeOH) in a 
60:40, MeOH:KH2PO4 ratio. The mobile phase 
was filtered using a 0.22 μm Stericup™ Sterile 
Vacuum Filter Unit and degassed by a vacuum 
stirring setup. 
 
2.4 Stock Solution and Samples 
Preparation 
 
Phenytoin was dissolved in HPLC-grade DMSO 
to produce a stock solution of 1 mg/mL 
concentration. The master stock was diluted with 
filtered human plasma to produce another stock 
solution of 100 μg/mL, which was further diluted 












Human plasma was passed through Millipore 
ultracentrifugation units, which were run at 
2,000X g for 20 minutes. The resulting filtrate 
was collected and used as a diluent for the PHT 
stock solution.  
 
3. METHOD VALIDATION 
 
The analytical method was validated based on 




The specificity of the method was determined by 
comparing blank (plasma without PHT) 
chromatogram to the chromatogram of a sample 
containing a known concentration of PHT. 
Analysis of the sample containing PHT showed a 
sharp peak at an elution time of 7.4 min, which 
was absent on the blank chromatogram (Figure 
1). Other components of filtered plasma were 
detected and separated by the method, allowing 
proper visualization of the PHT peak. The 




To determine linearity, eight phenytoin 
concentrations ranging from 1 to 25 μg/mL were 
prepared from the stock solution. Filtered human 
plasma was used to dilute the PHT stock solution 
into 1, 2, 4, 6, 8, 10, 15 and 25 μg/mL 
concentrations. The samples were assessed                 
to HPLC. The mean area for each                 
concentration was plotted against the 






Fig. 1. Blank Chromatogram (top) and Phenytoin Chromatogram (bottom): PHT concentration 




 Fig. 2. The linearity of the HPLC method 
 






























An excellent correlation was detected between 
the peak areas and concentrations tested (R
2
 = 
0.9998). All experiments were performed in 
triplicate. 
 
3.3 Limit of Detection and Limit of 
Quantitation 
 
The limit of detection (LOD) and limit of 
quantitation (LOQ) were calculated based on ICH 
guidelines [11]. The following formulas were 
used: 
 
LOD = 3.3*σ/S  




σ- refers to the standard deviation of the y-
intercept of the calibration curve  
S-  refers to the slope of the calibration curve.  
 
The calculated LOD and LOQ were at 0.07 




Accuracy study was performed with PHT 
concentrations of 5 μg/mL, 10 μg/mL and 20 
μg/mL. Triplicates were made to assess the 
accuracy. The results of the study are 
summarized in Table 2. The mean % recoveries 
of the three concentrations were found in the 
range of 99.21 - 102.09%. 
 




Limit of Detection (μg/mL) 0.07 
Limit of Quantitation (μg/mL) 0.20 
 
3.5 Precision / Repeatability 
 
Precision was determined by utilizing inter- and 
intraday testing. Phenytoin concentration of 25 
μg/ml was used in both studies. In the intraday 
study, six injections of different samples of 25 μg/ 
mL concentration were evaluated. In the interday 
study, an injection of six different samples of the 
same concentration (25 μg/mL) was done once a 
day for six consecutive days. The results of the 
study are summarized in Table 3. The results 
have been demonstrated low relative standard 
deviations (RSD) that indicate a precise method 
[28]. 
 
Table 2. Accuracy of the HPLC Method 
 




% Recovery Mean % 
Recovery 
1 5 5.01 100.28  
100.55 5.03 100.67 
5.03 100.68 
2 10 9.93 99.27  
99.21 9.91 99.15 
9.92 99.22 
3 20 20.26 101.28  
102.09 20.63 103.17 
20.36 101.81 
 
Table 3. Precision of the HPLC method 
 
Sample  Intraday Concentration(μg/mL) Interday Concentration(μg/mL) Day 
1 25.15 25.13 1 
2 24.90 25.14 2 
3 24.80 25.03 3 
4 24.85 25.16 4 
5 25.25 25.01 5 
6 25.03 24.97 6 
Mean 24.99 25.07  
SD* 0.16 0.07  
%RSD** 0.65 0.29  
*SD is Standard Deviation 











Table 4. Stability of phenytoin  
 
Initial 
PHT concentration (μg/mL) 
 
Stability conditions 
Human plasma Mobile phase 
RT, 4h 4℃, 24 h -30℃, 7days Freeze-Thaw 4ºC 24 h 
PHT concentrations (μg/mL) 
5 5.06 5.01 5.41 5.01 4.99 




The stability of phenytoin in human plasma             
was evaluated and the results are reported in                
Table 4.  
 
All the samples demonstrated stability for up to 
4 h at room temperature (RT), for 24 h at 4ºC, for 





The goal of the study was to develop               
and validate a simple and effective HPLC 
method to measure unbound phenytoin 
concentrations in human plasma. The    
analytical technique was fully validated. The 
novel HPLC method demonstrated phenytoin 
sharp peak, good resolution and no interferences 
from plasma constituents. The analytical 
procedure is a simple, fast, selective, precise  
and accurate method for quantitation of 
phenytoin in human plasma and may be    
utilized in studies where free phenytoin levels 
need to be measured. Detecting of free PHT 
plasma levels should be conducted to         
escape variations in pharmacologic response, to 
achieve the efficacy of phenytoin and to       
avoid phenytoin intoxication novel HPLC    
method has the necessary sensitivity to be     
used clinically for TDM (therapeutic drug 
monitoring) as well as for pharmacokinetics     
and drug: drug interaction studies. The this   
newly developed analytical technique has      
been applied for the drug: drug             
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